Clinical Scorecard: Real-World nAMD Treatment Patterns Reveal Cost of Switching
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular Age-Related Macular Degeneration (nAMD) |
| Key Mechanisms | Switching from low-cost compounded bevacizumab to branded anti-VEGF agents increases drug-related expenditures. |
| Target Population | Medicare patients with treatment-naïve wet AMD. |
| Care Setting | Ophthalmology clinics and Medicare settings. |
Key Highlights
- 54% of nAMD patients start treatment with bevacizumab.
- Switching to branded agents increases 3-year treatment costs from $700 to $20,000.
- 40% of bevacizumab starters switch to other agents within 3 years.
- Concerns about compounded drug quality may drive switching behavior.
- FDA is evaluating an ophthalmic formulation of bevacizumab (ONS-5010).
Guideline-Based Recommendations
Diagnosis
- Monitor patients for response to initial therapy with bevacizumab.
Management
- Consider cost implications when switching from bevacizumab to branded anti-VEGF agents.
Monitoring & Follow-up
- Assess treatment efficacy and patient adherence regularly.
Risks
- Inconsistent drug quality in compounded bevacizumab may lead to underdosing.
Patient & Prescribing Data
Medicare patients with neovascular age-related macular degeneration.
Most patients initially treated with bevacizumab switch to aflibercept or other branded agents.
Clinical Best Practices
- Evaluate the quality of compounded medications before prescribing.
- Educate patients on the cost implications of switching therapies.
- Encourage adherence to initial therapy to minimize costs.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.